Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries

Mesothelin (MSLN) is an attractive candidate of targeted therapy for several cancers, and hence there are increasing needs to develop MSLN-targeting strategies for cancer therapeutics. Antibody–drug conjugates (ADCs) targeting MSLN have been demonstrated to be a viable strategy in treating MSLN-posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Hung-Ju, Tung, Chao-Ping, Yu, Chung-Ming, Chen, Chi-Yung, Chen, Hong-Sen, Huang, Yu-Chuan, Tsai, Pei-Hsun, Lin, Su-I, Peng, Hung-Pin, Chiu, Yi-Kai, Tsou, Yueh-Liang, Kuo, Wei-Ying, Jian, Jhih-Wei, Hung, Fei-Hung, Hsieh, Chiao-Yun, Hsiao, Michael, Chuang, Simon Shih-Hsien, Shen, Chia-Ning, Wang, Yong Alison, Yang, An-Suei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322431/
https://www.ncbi.nlm.nih.gov/pubmed/34326410
http://dx.doi.org/10.1038/s41598-021-94902-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322431/
https://www.ncbi.nlm.nih.gov/pubmed/34326410
http://dx.doi.org/10.1038/s41598-021-94902-1

Ejemplares similares